Cargando…

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

BACKGROUND: Clinical trials have shown the ability of therapeutic vaccines to generate immune responses to tumor-associated antigens (TAAs). What is relatively less known is if this translates into immune-cell (IC) infiltration into the tumor microenvironment. This study examined whether neoadjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdul Sater, Houssein, Marté, Jennifer L, Donahue, Renee N, Walter-Rodriguez, Beatriz, Heery, Christopher R, Steinberg, Seth M, Cordes, Lisa M, Chun, Guinevere, Karzai, Fatima, Bilusic, Marijo, Harmon, Stephanie A, Turkbey, Ismail Baris, Choyke, Peter L, Schlom, Jeffrey, Dahut, William L, Madan, Ravi A, Pinto, Peter A, Gulley, James L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174144/ https://www.ncbi.nlm.nih.gov/pubmed/32269146 http://dx.doi.org/10.1136/jitc-2020-000655

Ejemplares similares

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report
por: Monge, Cecilia, et al.
Publicado: (2018)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
por: Strauss, Julius, et al.
Publicado: (2020)

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
por: Madan, Ravi A, et al.
Publicado: (2021)

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
por: Marté, Jennifer L, et al.
Publicado: (2020)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2020)

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
por: Gatti‐Mays, Margaret E., et al.
Publicado: (2019)

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
por: Bilusic, Marijo, et al.
Publicado: (2022)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma
por: DeMaria, Peter Joseph, et al.
Publicado: (2021)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

A case report of multiple primary prostate tumors with differential drug sensitivity
por: Wilkinson, Scott, et al.
Publicado: (2020)

Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans
por: MASOUDI, SAMIRA, et al.
Publicado: (2021)

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
por: Gulley, James L., et al.
Publicado: (2019)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
por: Karzai, Fatima, et al.
Publicado: (2018)

Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
por: Kim, Joseph W., et al.
Publicado: (2012)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
por: Mandl, Stefanie J, et al.
Publicado: (2014)

Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
por: Heery, Christopher R., et al.
Publicado: (2016)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

A comparison of prostate cancer bone metastases on (18)F-Sodium Fluoride and Prostate Specific Membrane Antigen ((18)F-PSMA) PET/CT: Discordant uptake in the same lesion
por: Harmon, Stephanie A., et al.
Publicado: (2018)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
por: Lepone, Lauren M., et al.
Publicado: (2016)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care
por: Karzai, Fatima, et al.
Publicado: (2022)

Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates
por: Kobayashi, Hisataka, et al.
Publicado: (2014)

Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy
por: Lucas, Julie L., et al.
Publicado: (2017)

Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence
por: Ku, Anson T., et al.
Publicado: (2023)

Quick guide on radiology image pre-processing for deep learning applications in prostate cancer research
por: Masoudi, Samira, et al.
Publicado: (2021)

Application of Spectral Algorithm Applied to Spatially Registered Bi-Parametric MRI to Predict Prostate Tumor Aggressiveness: A Pilot Study
por: Mayer, Rulon, et al.
Publicado: (2023)

Relationship between Eccentricity and Volume Determined by Spectral Algorithms Applied to Spatially Registered Bi-Parametric MRI and Prostate Tumor Aggressiveness: A Pilot Study
por: Mayer, Rulon, et al.
Publicado: (2023)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6n572ktd4o7p5nf438tfsp0n8c